Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Verheyen, N; Wetzel, J; Martensen, J; Belyavskiy, E; Schmidt, A; Colantonio, C; Catena, C; Gaksch, M; Grübler, MR; Kraigher-Krainer, E; Pieske, B; Meinitzer, A; Rus-Machan, J; Fahrleitner-Pammer, A; Pilz, S; Tomaschitz, A.
9B.05: ASSOCIATION OF PLASMA PARATHYROID HORMONE WITH NIGHTTIME BLOOD PRESSURE IN PRIMARY HYPERPARATHYROIDISM-THE "EPLERENONE IN PRIMARY HYPERPARATHYROIDISM" TRIAL.
J Hypertens. . 2015; 33 Suppl 1(10):e121-e121. [Oral Communication]
PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Belyavskiy Evgeny
Colantonio Caterina
Fahrleitner-Pammer Astrid
Gaksch Martin
Grübler Martin Robert
Martensen Johann
Meinitzer Andreas
Pieske Burkert Mathias
Pieske-Kraigher Elisabeth
Pilz Stefan
Schmidt Albrecht
Tomaschitz Andreas
Verheyen Nicolas Dominik
Wetzel Julia
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
High parathyroid hormone (PTH) is a cardiovascular risk factor. Elevated plasma PTH levels are independently linked with high nighttime blood pressure (BP) in hypertensive patients. We therefore investigated the association between PTH and nighttime BP in patients with primary hyperparathyroidism (pHPT). We analyzed patients with pHPT who participated in the "Eplerenone in Primary Hyperparathyroidism" (EPATH) Trial. Blood sampling was performed after an overnight fast and all laboratory parameters were determined immediately after blood sampling. 24-hour ambulatory BP monitoring was performed using a certified device (Mobil-O-Graph, I.E.M., Stolberg, Germany). Patients with regular use of the PTH modifying drug cinacalcet or with a reduced left ventricular ejection fraction <= 45% were excluded. We enrolled 120 patients (mean age: 66 +/- 10 years, 98 were females [82%]). Median PTH (IQR) was 94 pg/mL (79 - 113), mean systolic and diastolic nighttime BP were 117 +/- 17 mmHg and 68 +/- 10 mmHg, respectively. PTH was directly correlated with mean systolic and mean diastolic nighttime BP (Spearman rho = 0.246, p = 0.007; rho = 0.214, p = 0.019, respectively). In multivariate linear regression analyses adjusted for age, sex, cholesterol, HbA1c, intake of antihypertensive drugs, 25-hydroxy vitamin D and glomerular filtration rate (CKDEPI), PTH remained significantly related to mean systolic nighttime BP (adjusted beta-coefficient = 0.194, p = 0.047), while the relationship with mean diastolic nighttime BP was not significant (beta = 0.260, p = 0.109). Plasma PTH was associated with mean systolic nighttime BP in patients with pHPT, independently of potential confounders. These novel data from the EPATH Trial further support the notion that PTH directly interferes with nighttime BP regulation. Whether lowering circulating PTH concentrations reduces the burden of high BP remains to be shown in future studies.

© Meduni Graz Impressum